Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(67%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
2
67%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_3

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

NCT06736509
terminatedphase_2

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669
completedphase_3

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT04947553

Clinical Trials (3)

Showing 3 of 3 trials
NCT06736509Phase 3

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

Terminated
NCT04634669Phase 2

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Terminated
NCT04947553Phase 3

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3